FTC Submission: Competition and Consumer Protection in the 21st Century
Amicus Brief Filed in RPX Corp. v. Chanbond LLC: Patient and public interest actors should have the same rights as drugmakers to appeal IPR decisions to the courts to prevent unmerited patents.
Submission to Health and Human Services: I-MAK response to Blueprint to Lower Drug Prices
Letter to the USPTO Director
Submission to Chinese FDA: more exclusivity will harm patients